Editorial-Orientierung von MedAPI — kein Bestandteil der Kodieranweisung.
ICD-10-CM family C06 covers primary malignant neoplasms arising in other or unspecified parts of the mouth, including the cheek (buccal) mucosa, oral vestibule, and retromolar area. It also includes overlapping lesions within these sites when the point of origin cannot be determined and mouth cancers documented without a more specific oral site.
Common Histologies
- Squamous cell carcinoma is by far the most common histology.
- Less common tumors include minor salivary gland carcinomas, mucosal melanoma, sarcomas, and other rare malignancies.
- Important risk factors include tobacco exposure, heavy alcohol use, betel quid or areca nut use, chronic immunosuppression, and certain inherited cancer-predisposition syndromes.
Common Symptoms
- Persistent oral ulcer (K12.0), plaque (K03.6), or mass (K13.70)
- Pain (R52), burning (R20.8), bleeding (R58), or nonhealing mucosal change (K13.79)
- Trismus, particularly with retromolar involvement (M26.52)
- Difficulty chewing (R13.11), swallowing (R13.10), or fitting dentures (Z46.3)
- Referred ear pain (H92.09), facial sensory change (R20.8), reduced tongue (R43.8), or jaw mobility (M26.52)
- Cervical lymphadenopathy (R59.0)
- Weight loss or nutritional impairment in advanced disease (E88.A) (E88.A)
Diagnosis
Evaluation generally includes careful inspection and palpation of the entire oral cavity and neck, with biopsy for histopathologic confirmation. Imaging with contrast-enhanced CT or MRI helps define local soft-tissue, mandibular, maxillary, masticator-space, or perineural involvement. Ultrasound, CT, MRI, or PET/CT may be used to assess cervical nodes and distant disease according to clinical stage.
Documentation should identify the most specific site possible, such as cheek mucosa, vestibule, or retromolar area. Adjacent structures—including the lip, tongue, floor of mouth, palate, major salivary glands, and oropharynx—have separate ICD-10-CM site families.
Staging
These cancers are generally staged using the oral cavity TNM system. Key features include:
- Maximum tumor dimension and depth of invasion
- Invasion of adjacent bone, skin, deep muscles, or other structures
- Number, size, laterality, and location of involved cervical lymph nodes
- Extranodal extension
- Presence of distant metastases
Stage is determined separately from the ICD-10-CM site code.
Molecular Markers
Routine biomarker use depends on histology and treatment setting. For conventional oral cavity squamous cell carcinoma, HPV-associated biology is less central than in oropharyngeal carcinoma, and p16 positivity alone should not be interpreted as establishing an HPV-mediated oral cavity primary. Broader molecular testing may be appropriate in recurrent, metastatic, or unusual tumors; PD-L1 assessment may help guide systemic therapy in selected advanced squamous cell carcinomas.
Common Treatments
Management is multidisciplinary and depends on site, resectability, stage, functional impact, and patient factors.
- Surgery is commonly the primary treatment for resectable oral cavity cancers, with reconstruction as needed.
- Neck dissection or sentinel-node evaluation may be considered based on nodal status and risk of occult metastasis.
- Adjuvant radiation therapy may be used for adverse pathologic features.
- Concurrent chemoradiation may be indicated for selected high-risk findings, such as positive margins or extranodal extension.
- Definitive radiation-based treatment may be used when surgery is not feasible or would cause unacceptable morbidity.
- Recurrent or metastatic disease may be treated with immunotherapy, cytotoxic chemotherapy, targeted therapy in selected histologies, surgery, radiation, or symptom-directed care.
- Dental assessment, nutrition, speech and swallowing rehabilitation, tobacco cessation, and alcohol-risk management are important supportive measures.
Scope Note
C06 encodes the anatomic site of a primary malignant neoplasm in other or unspecified parts of the mouth. Its child codes distinguish cheek mucosa, oral vestibule, retromolar area, overlapping C06 sites, and an unspecified mouth site. The code does not encode histologic subtype, grade, TNM stage, depth of invasion, nodal status, molecular findings, or treatment. It should not be used to represent a secondary or metastatic deposit in the mouth, and a more specific site family should be used when the primary is documented in structures such as the lip, tongue, floor of mouth, palate, salivary gland, or oropharynx. Associated tobacco or alcohol conditions may be documented separately when clinically present.